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Clonogenicity: Holoclones and Meroclones Contain Stem
Cells
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Abstract
When primary cultures of normal cells are cloned, three types of colony grow, called holoclones, meroclones and
paraclones. These colonies are believed to be derived from stem cells, transit-amplifying cells and differentiated cells
respectively. More recently, this approach has been extended to cancer cell lines. However, we observed that meroclones
from the prostate cancer cell line DU145 produce holoclones, a paradoxical observation as meroclones are thought to be
derived from transit-amplifying cells. The purpose of this study was to confirm this observation and determine if both
holoclones and meroclones from cancer cell lines contain stem cells. We demonstrated that both holoclones and
meroclones can be serially passaged indefinitely, are highly proliferative, can self-renew to form spheres, are serially
tumorigenic and express stem cell markers. This study demonstrates that the major difference between holoclones and
meroclones derived from a cancer cell line is the proportion of stem cells within each colony, not the presence or absence of
stem cells. These findings may reflect the properties of cancer as opposed to normal cells, perhaps indicating that the
hierarchy of stem cells is more extensive in cancer.
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Introduction
The relationship between stem cell capacity and colony forming
ability of primary keratinocytes was established in a seminal paper
by Barrandon and Green [1]. Using primary cultures of human
keratinocytes, Barrandon and Green found that single cells
produced 3 types of colony (which they termed holoclones,
meroclones and paraclones) derived from cells with different
proliferative capacities. Only holoclones are capable of extensive
proliferation and self-renewal, whilst meroclones have a limited
proliferative capacity and cannot self-renew and paraclones are
incapable of further proliferation. The terms holoclone, meroclone
and paraclone have since become synonymous with colonies
derived respectively from stem, early and late stage transit-
amplifying cells [1,2].
The hierarchy of colony forming cells described by Barrandon
and Green is recapitulated by certain types of normal cell in
culture [3,4] and consequently colony morphology is used
routinely as a surrogate assay to identify and characterize stem
cells from skin [5,6], follicular [7] and limbal [8,9] tissues. The
assay is also used to evaluate stem cells for use in tissue engineering
[6]. Holoclones express survival and self-renewal genes associated
with stem cell capacity, such as p63 [8] and BMI-1 [10]. In these
studies, the colonies and not the individual cell they are derived
from are referred to as holoclones, meroclones and paraclones.
Subsequently, holoclones, meroclones and paraclones were
described in clones derived from human cancer cell lines of various
types, including pancreatic [11], head and neck [12], breast [13]
and prostate [14–18]. Cancer cell holoclones can be passaged
indefinitely [14] and xenografted serially [17]. The formation of
holoclones has been adopted as a surrogate stem cell assay,
particularly in the study of prostate cancer [19–22]. An increased
number of holoclones is regarded as enrichment for cancer stem
cells (CSC) and has been used to study CSC marker expression. In
prostate cancer an increased number of holoclones is associated
with the expression of the putative stem cell markers CD44,
integrin a2b1, CD133 [14,17], PSAlo expression [23] and
aldehyde dehydrogenase 1 (ALDH) activity [20]. Holoclone
formation has also been used to validate sphere formation from
cell lines as a stem cell assay [24] and to demonstrate the presence
of cancer stem cells in samples from primary human prostate
cancers [25]. In addition, holoclone formation has been used to
demonstrate enrichment of cancer stem cells in side population
ovarian cancer cells [26] and in CD133 [27] and [12] CD44
expressing oral squamous cancer cell lines.
We set out to use the colony forming assay as a surrogate
marker to identify genes that control self-renewal in prostate
cancer cells. However, we observed that colonies derived from
meroclones (putatively derived from transit-amplifying cells) were
able to produce holoclones (stem cell colonies), albeit at a lower
frequency than the colonies derived from holoclones. This
observation calls into question the widely held and applied
assumption that colonies with the three characteristic morpholo-
gies are derived from stem, early and late transit-amplifying cells
respectively.
We therefore set out to re-investigate the relationship between
clonogenicity and stem cell capacity in cancer cells by studying the
colony forming ability, transplantation capacity and marker
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expression of each morphological type of colony derived from the
prostate cancer cell line DU145. We tested the hypothesis that the
cancer cell colonies differ in the proportion, rather than the
presence or absence, of stem cells. The results support this
hypothesis. The experiments did not test the original findings of
Barrandon and Green, which were based on normal cells, and
consequently may indicate that self-renewal capacity is extended
further down the stem cell hierarchy in cancer.
Materials and Methods
Cell Culture
The prostate cancer cell line DU145 was obtained from its
originator [28] and maintained in 25 cm2 culture flasks containing
growth medium RMPI-1640 (Invitrogen, UK) supplemented with
10% FBS (PAA, UK) and 2 mM L-Glutamine (Invitrogen) at
37uC in 5% CO2. A single cell suspension was prepared by
incubating cells with 0.25% trypsin for 10 min and counted using
trypan blue exclusion. To determine colony forming efficiency and
for serial cloning, 200 single cells were seeded into 60 mm
diameter petri-dishes with 5 ml growth medium and incubated for
two weeks until macroscopic colonies were visible. To check the
proportion of colonies that arise from single cells, colony growth
was monitored by the Incucyte Live Cell Imaging System from
initial adherence every 4 hours for 2 weeks.
Colony Analysis
Following 2 weeks incubation, dishes were fixed by removal of
culture medium and the addition of 70% IMS. Colonies were
stained with 0.1% crystal violet (Sigma-Aldrich) and the number
and type of colonies counted. Total CFE and the CFE of each
colony type was calculated as a percentage of the number of cells
seeded. Using a graticule and eye piece, the colony was measured
across perpendicular axes to estimate the area of each colony. The
number of cells across the diameter was counted and thus the area
per cell and the total cell number per colony were estimated. To
determine average colony dimensions, 20 colonies of each type
were measured and the number of cells in each colony calculated.
Secondary Cloning
Colonies were inspected under a light microscope and scored on
morphology and the size and number of cells per colony was
determined as described above. Fifteen well isolated colonies of
each type were selected and ring cloned by placing a glass cloning
ring around the colony sealed with vacuum grease and trypisinised
by adding 75 ml trypsin for 5 min. The colony was resuspended in
medium, transferred to fresh 60 mm diameter petri dishes at a
density of 200 cells per dish and incubated for a further 2 weeks.
Dishes were fixed and stained with crystal violet and the CFE
determined.
Serial Cloning
In three separate experiments, three colonies of each type were
serially cloned for up to 10 passages. Colonies were ring cloned for
secondary cloning as described above and resultant colonies were
then serially cloned using the same method. Each lineage was
serially cloned up to 10 times or until the colony was terminal. As
meroclone were able to form secondary holoclones, these
secondary holoclones were also serially cloned. Remaining dishes
at each generation were fixed with 70% IMS and stained with
0.1% crystal violet (Sigma-Aldrich) for analysis of CFE and colony
morphology.
Serial Passage (Bulk)
Fifteen colonies of each type were ring cloned as described
above and transferred to a 25 cm2 flask containing culture
medium. Each clone was incubated until 70–90% confluent and
passaged 1 in 6 for up to 20 passages. Clones that failed survive to
reach confluency were monitored for the duration of the
experiment, until all surviving clones reached 20 passages.
Sphere Forming Assay
Ring cloned DU145 colonies were seeded at a density of 1000
cells per well of 6 well plate in 135 ml sphere culture medium
(serum-free DMEM/F12 medium, 20 ng/ml basic FGF, 20 ng/
ml EGF 1x B27 (all Invitrogen) and 3 mg/ml insulin (Sigma))
mixed 1:1 with 135 ml Matrigel Basement Membrane Matrix (BD
Bioscience, Michigan, USA) and pipetted gently around the edges
of a 6 well plate (Nunc). The plate was incubated at 37uC for
15 min until the Matrigel had set. It was covered with 3 ml sphere
culture medium and incubated for 2 weeks with a 50% medium
change at 7 days. Following 14 days incubation, spheres were
counted and their diameter measured using an eye piece and
graticule to determine sphere forming efficiency (% SFE) and
sphere size.
Xenograft Tumor Formation
This study was performed in accordance with the recommen-
dations in the Guidelines for the welfare and use of animals in cancer
research and every effort was made to minimize suffering [29]. The
work was carried out under the authority of Home Office, UK,
approved project licence (PPL 70/7244). Holoclones and
meroclones were harvested, pooled. 10,000 or 1,000 cells were
resuspended 1:1 in RPMI/Matrigel mixture and injected subcu-
taneously into the flanks of 7 week old male Nude mice (Harlan,
UK). Mice were inspected for tumor growth by palpation and
tumor growth was measured weekly using a digital caliper (WPI,
Florida, USA). Tumor growth was determined using the formula
a6b260.5, where a is the longer and b the shorter of the two
perpendicular diameters. Mice were killed by cervical dislocation
at 12 weeks and tumors removed and weighed.
Tumors were minced into ,1 mm3 pieces in RPMI-1640
containing 10% FBS and 100 U/mL Penicillin/streptomycin
(Invitrogen) and washed twice with the same medium and then
digested in 10 ml/g tissue of 600 Uml collagenase (Invitrogen) for
2 hours at 37uC with gentle shaking. The resulting cell suspension
was washed and a single cell suspension obtained by filtering
through a 40 mm cell strainer. The single cell suspension was used
to measure clonogenicity and for serial xenotransplantation.
Fluorescence Immunocytochemistry
Colonies grown at a density of 10 cells per well in 24 well plates
for 2 weeks were fixed with 4% PFA for 20 min at room
temperature. Colonies stained for intracellular markers (Ki67, K5,
K18, BMI-1 and Oct4) were permeabilised by adding 200 ml 0.2%
Triton X-100 (Sigma-Aldrich) in PBS for 10 min at room
temperature. Non-specific staining was blocked by incubating
the colonies for 30 min with 10% normal goat serum (NGS) (PAA)
at room temperature. Primary antibodies (Table S1) (Abcam, UK)
diluted in 10% NGS in PBS were incubated overnight at 4uC,
washed 4 times and incubated with FITC-conjugated secondary
antibodies (Southern Biotech) for 1 h at room temperature.
Finally, the colonies were washed, dried and mounted using
Vectashield containing DAPI (Vector Laboratories Inc, Peterbor-
ough, U.K.). Colonies were viewed using Olympus Total Internal
Reflection inverted confocal microscope and Fluoview 2000
Clonogenicity and Stem Cells
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software. The marker positive fraction was calculated as a
percentage of total cell number (number of DAPI stained nuclei).
Statistical Analysis
The properties of each colony type were analysed by one way
analysis of variance (ANOVA) or Multivariate analysis of variance
(MANOVA) followed by Tukey’s honestly significant difference
(HSD) post hoc pairwise comparison using the statistics package
PAWS Statistics 18 (formerly SPSS). Results displayed as
percentages were analysed following arcsine transformation. p
values of less than 0.05 were deemed significant.
Results
DU145 cells form three types of colony (Figure 1A), with
morphologies characteristic of holoclones, meroclones and para-
clones [18] The number of cells in each colony was estimated by
measuring the diameters of twenty colonies of each type and
determining the number of cells across the diameter. Holoclones
are large with smooth edges and consist of small tightly packed
cells with a mean density of 14706400 cells/cm2. Meroclones are
smaller, have an irregular outline and consist of a mixture of small
tightly packed cells and much larger loosely packed cells,
particularly around the edge, with an average cell density of
7536218 cells/cm2. Paraclones are small and diffuse and consist
mainly of loosely packed enlarged cells with a mean density of
261674 cells/cm2.
Colony Forming Efficiency (CFE)
In order to measure secondary CFE, 30 colonies of each type
were cloned and plated at 200 cells/6 cm dish in triplicate and the
numbers of each type of colony produced were counted
(Figure 1B). Holoclones and meroclones produced similar
numbers of secondary colonies overall, whereas paraclones
Figure 1. Clonogenicity of DU145 prostate cancer cell line. (A)
Single DU145 cells form colonies of three morphological types termed
holo-, mero-, and paraclones (pictured) Bar = 200 mm. (B) Type 1 (left)
and type 2 (right) colonies which were ring cloned and cultured at
clonal density formed secondary colonies. The secondary colony
forming efficiency (CFE) and types of secondary colonies were
determined. Paraclone were unable to from secondary colonies.
doi:10.1371/journal.pone.0089834.g001
Table 1. Number of Cell Divisions during Serial Cloning.
Generation Holoclone
Holoclone from
Meroclone Meroclone
1 3222 (11) 1650 (10) 1650 (10)
2 4385 (12) 2752 (11) 801 (9)
3 11700 (13) 3728 (11) 1104 (10)
4 3320 (11) 5344 (12) 1364 (10)
5 7695 (12) 3029 (11) 668 (9)
6 3521 (11) 2843 (11) 947 (9)
7 5470 (12) 1849 (10) 636 (9)
8 3029 (11) 1923 (10) 2
9 7847 (12) 2237 (11) 2
10 3728 (11) 665 (9) 2
11 12693 (13) 3222 (11) 2
Total Number 129 117 66
Each colony type was serially cloned and the proliferative capacity of each clone
determined. Colony size was used to estimate the number of cell divisions at
each generation displayed as mean cell number and minimum number of cell
divisions in brackets. The sum of divisions at each generation provides an
estimate of how many total cell divisions the original cell which formed the
original colony of each type can undergo.
doi:10.1371/journal.pone.0089834.t001
Table 2. Tumorigenicity of DU145 colonies.
Cell Type Number of Cells Injected Tumor Incidence Latency (d)
DU145 Monolayer 10000 5/6 37.8 (11)
1000 4/8 41.8 (9)
Holoclone 10000 4/9 30.5 (8)
1000 4/12 49.5 (13)
Meroclone 10000 2/7 47 (4)
1000 4/16 61.5 (3)
Paraclone 1000 0/4 2
Vehicle Control 0 0/12 2
DU145 colonies were pooled and were injected s.c into the flanks of Nude mice in a mixture of 1:1 Matrigel: RPMI. Vehicle control (VC) animals received and injection of
Matrigel: RPMI alone. Tumor latency was determined as the first day tumours were palpable and animals sacrificed after 12 weeks and tumors weighed. Mean latency
and tumor weights display, standard error in brackets.
doi:10.1371/journal.pone.0089834.t002
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produced few or no secondary colonies. The major difference
between holoclones and meroclones was the number of secondary
holoclones produced. Holoclones produced mainly holoclones,
whereas meroclone colonies produced slightly more meroclones
than holoclones. The production of holoclones from meroclones is
paradoxical as this finding would suggest that colonies derived
from transit-amplifying cells can produce stem cell colonies.
Therefore we tested the hypothesis that holoclones and mer-
oclones differ only in the proportion of stem cells.
Can Each Type of Colony be Serially Cloned?
To determine if both holoclones and meroclones have indefinite
proliferative capacity, the serial colony forming capacity of each
colony type was measured. 3 holoclones and 3 meroclones were
picked, and re-cloned at 200 cells/5 cm dish in triplicate.
Holoclones from holoclones and meroclones from meroclones
were serially cloned up to 17 times as for the first cloning.
Additionally, holoclones derived from original meroclones follow-
ing the first round of cloning were also serially cloned a further 10
times in the same way. Based on the estimate of the number of
cells in each colony, it was possible to calculate the number of cell
divisions needed to produce each colony. This calculation was a
crude estimate as it assumed no cell loss and identical reproductive
capacity throughout the colony (Table 1). Over the course of the
experiment, it was calculated that the holoclones derived from
holoclones had undergone a minimum of 129 cell divisions,
holoclones derived from meroclones 117 cell divisions, whereas the
meroclones derived from meroclones died out after 66 cell
divisions. Both the holoclones derived from holoclones and
meroclones continued to produce further holoclones for the
duration of the experiment, whereas the serial meroclones
continued to produce holoclones for only 4 rounds and died out
after 7 rounds of cloning.
Can Each Type of Colony be Serially Passaged?
In order to study self-renewal capacity using an alternative
method, 5 holoclones and 5 meroclones were ring-cloned and
transferred in bulk to T25 flasks. The experiment was repeated 3
times. 14/15 (93%) of holoclone and 10/15 (67%) meroclones
were still growing at the same rate after 20 passages. Initially, the
growth rate of holoclones was faster than that of meroclones.
However, after 4 weeks, the growth rates of cells derived from the
two colony types were similar and each clone showed the typical
morphology of DU145 cells grown in a monolayer.
Can Each Type of Colony form Spheres?
The sphere-forming assay is used as a measure of self-renewal.
In three experiments, 3 of each type of colony were harvested and
plated at 1000 cells/well in a 6 well plate in triplicate. Holoclones
had a sphere forming efficiency of 15.3% 63.1% compared to
5.9% 62.7% for meroclones (p,0.05, one-way ANOVA). The
spheres formed by holoclones were larger than those of
meroclones with a mean diameter of 105 mm 65.1 mm compared
to 63 mm 66.3 mm. Paraclones were unable to form spheres.
Tumorigenicity
Colonies of each type were transplanted subcutaneously into the
flanks of nude mice. The data for holoclones were based on
individual colonies, whereas those for meroclones and paraclones
were based in part on pooling colonies to provide the number of
cells required (Table 2).
Holoclones and meroclones, but not paraclones, were able to
initiate tumor development in nude mice (Figure 2A–D). There
was little difference between holoclones and meroclones in their
ability to develop cancers, but meroclones had a longer latency
and the tumours did not grow as large over the 12 week period as
those derived from holoclones (Figure 2E). Cells isolated from the
transplanted tumors and cultured in vitro in a clonogenic assay
recapitulated the three colony types in similar proportions to the
original cell line and could be xenografted (Figure 2F).
Does the Proliferative Fraction of the Three Colony Types
Differ?
From three experiments, a total of 20 colonies of each type were
fixed in paraformaldehyde and stained for Ki-67. The majority of
Figure 2. Tumourigenicity of DU145 colonies. DU145 colonies of
each type were injected subcutaneously into the flanks of nude mice.
Holoclones (A) and Meroclones (B) both formed tumours which were
excised and stained with H&E (C&D). (E) The tumours derived from
10000 cells were measured by digital callipers across 2 diameters at
180u weekly and tumor volume calculated (mean 6 S.E.). (F)
Clonogenicity of tumors. Following dissection, tumors were digested
in collagenase to produce a single cell suspension. 200 cells were
seeded into petri dishes to determine colony forming efficiency (%) and
the types of colonies formed by tumors of parent colonies.
doi:10.1371/journal.pone.0089834.g002
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PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e89834
the cells in all 3 types of colony were Ki-67 positive (Figure 3), with
86.663.6% positive in holoclones, 71.763.3% in meroclones and
58.967.5% in paraclones. Ki-67 expression was spread evenly
throughout the colonies.
Do the Colonies Differ in Marker Expression?
From three experiments a total of 20 colonies of each type
growing in 24 well plates were fixed in paraformaldehyde and
stained for each marker.
Cytokeratin 18 (K18) is characteristic of prostate epithelial
luminal cells, while cytokeratin 5 (K5) is characteristic of the less
differentiated basal cells. All the cells in all three colony types
expressed K18, but no cells expressed K5 (Figure 4).
Colonies were stained for 4 markers for which there is evidence
of association with epithelial stem cells in the human prostate,
namely CD44, a2b1 integrin, Oct4 and BMI-1. Over 80% of the
cells in holoclones stained for all the markers. The intensity of
CD44 and a2b1 integrin was variable, with more intensely
staining cells tending to be located around the periphery of the
colony. Meroclones had a similar number of Oct4, BMI-1 and
a2b1 integrin positive cells as holoclones, but contained fewer
a2b1 integrin cells (figure 4 B). Paraclones were negative for a2b1
integrin, BMI-1 and Oct-4 and contained fewer CD44 positive
cells than the holoclones and meroclones (p,0.05 MANOVA).
Are Colonies Derived from Single Cells?
The ability to generate single cell suspensions for the purpose of
cloning has not been previously checked systematically. The single
cell origin of DU145 colonies was checked by time lapse
photography using the Incucyte imaging system (Figure 5A). In
each of five separate experiments, the origins of 30–50 colonies
were determined by back-tracking. Although the majority of
colonies were derived from single cells, it was observed that some
colonies originated from multiple cells or from colonies which
merged and by the time of fixation appeared to be one colony
(Figure 5B). Of the holoclones, 72.9% 69.8% were derived from
single cells, compared to 89.565.2% and 89.2% 65.5% of
meroclone and paraclones.
Discussion
The aim of this study was to test the hypothesis that holoclones
and meroclones derived from a human cancer cell line differ only
in the proportion of stem cells each contains. Both holoclones and
meroclones contain cells which are highly proliferative, immortal,
can self-renew and are serially tumorigenic, but in differing
proportions. The evidence strongly supports the hypothesis and
suggests that colony morphology cannot be used as a surrogate
marker for a stem cell origin.
Tumours are believed to contain a hierarchy of cells headed by
cancer stem cells (CSC) which can self-renew and differentiate to
produce the multiple cell types observed within the cancer. To be
considered a CSC, a cell must be able to self-renew, differentiate
and be serially tumorigenic [30]. The results of this study show
that both DU145 holoclones and meroclones contain cells with
stem cell properties.
Figure 3. The proliferative fraction of DU145 colonies types determined by Ki67 staining. The percentage of Ki67 positive cells was
determined by counting the number of green (FITC) cells as a proportion of blue DAPI positive nuclei. Representative colonies shown.
doi:10.1371/journal.pone.0089834.g003
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The first indication that DU145 meroclones contained self-
renewing cells came from data demonstrating that both holoclones
and meroclones can form all three secondary colony types,
whereas paraclones have little self-renewal capacity. Self-renewal
was further demonstrated by sphere formation by both holoclones
and meroclones. The lower sphere forming efficiency and
tendency of meroclones to form fewer holoclones suggests that
meroclones contain a smaller proportion of self-renewing stem
cells than holoclones.
Both holoclones and meroclones contained immortal cells
which, when serially cloned, could be cultured for more than
100 divisions, whereas paraclones were terminal. Cancer stem cells
are usually considered immortal and undergo many cell divisions
to drive tumor growth and metastasis [31]. Both holoclones and
meroclones were serially engrafted in nude mice. This assay is
considered the gold standard for the identification of cancer stem
cells [30]. Meroclones had a longer latency than holoclones and
formed smaller tumours, again suggesting that meroclones contain
fewer stem cells than holoclones.
CD44 and a2b1 integrin are markers that to enrich for a
prostate cancer stem cell population [32]. a2b1 integrin was
expressed at high levels in holoclones and meroclones but not
paraclones, whilst CD44 was observed in holoclones and
meroclones and at lower levels in paraclones. Another contrasting
study has shown no difference between the growth rates of PC-3
cells in high cell density culture and showed no difference in CD44
and a2b1 expression [32], so these markers alone do not confirm
CSC identity.
Holoclones and meroclones were positive for BMI-1, an
oncogene suggested to play a role in stem cell self-renewal [33]
Figure 4. Expression of epithelial and stem cell markers by DU145 colonies. Expression of luminal (K18) and basal (K5) epithelial and stem
cell markers (CD44, a2b1 integrin, Oct4 and BMI1) in DU145 colonies was determined by immunocytochemistry. (A) Holo, mero and paraclone DU145
colonies were stained by immunocytochemistry with monoclonal antibodies against the target, detected with a FITC conjugated secondary antibody
(Green) and counter stained with DAPI (blue). (B) The number of positive cells for each maker were determined as a percentage of the total number
of cells counted. Holoclone and meroclones contained more CD44 positive cells than paraclones. Hololcones colonies contained more a2b1 positive
cells than meroclones. p,0.05 (MANOVA).
doi:10.1371/journal.pone.0089834.g004
Clonogenicity and Stem Cells
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and which has been previously shown to be up-regulated in
pancreatic cancer cell holoclones [11]. The embryonic stem cell
marker Oct-4 was observed in stem and transit-amplifying
colonies, but not in paraclones, suggesting a role in self-renewal
and differentiation [34]. Previous studies have shown that stem cell
colony formation is controlled by factors involved in self-renewal,
such as Nanog [35], telomerase [21] and microRNA miR-34a
which controls CD44 expression [19].
A number of studies using prostate [14,16,17,32] pancreatic
[11] colo-rectal [36], breast [13], head and neck squamous cell
caancer [12] and uveal melanoma [37] cancer cell lines have tried
to validate the use of colony morphology as a surrogate marker to
define colonies derived from stem cells, transit-amplifying cells and
differentiating cells. The results are surprisingly disparate and are
in contrast to our findings. All previous studies conclude that
holoclones have a greater ability to be passaged in bulk culture
[11,17] or by serial cloning [11,14,16,37] than paraclones, and
that paraclones with a differentiated morphology have a very
limited proliferative potential. In these studies, meroclones were
either not grown [14,16] or could only be propagated for about 3
months compared to more than 6 months for holoclones [17]. The
ability of cells derived from meroclones to generate secondary
holoclones was observed in one study, but few holoclones were
formed from meroclones [11].
Previous studies have shown that only holoclones are tumori-
genic in vivo [11,17] or that holoclones form larger, faster growing
tumors than paraclones [32,36,38]. Again, the majority of these
studies only compared holoclones and paraclones. The ability of
some paraclones to form tumours in some of these studies is
paradoxical as it indicates that some paraclones contain stem cells.
Holoclones formed by the prostate cancer cell line PC-3 are
highly tumorigenic, can be passaged long term and express the
cancer stem cell markers a2b1+ CD44+ [17]. However,
holoclones and meroclones are difficult to distinguish in cultures
of PC-3 [16,18].
It appears that colony morphology is a good predictor of stem
cell origin in primary cultures derived from normal cells, but not
cancer cell lines. In cancer, stem cell capacity may be shifted
further down the cellular hierarchy towards differentiation,
resulting in transit amplifying cells acquiring stem cell properties.
Using the Incucyte to track cell growth it was found that the
majority of DU145 colonies are derived from single cells. A
proportion of colonies were derived by the fusion of two colonies
or from small clumps of cells. It is well known that some cell lines,
such as LNCaP, are more prone to clumping and therefore
produce fewer single cell derived colonies [39]. The results of this
study show that the colony morphology of cancer cell lines cannot
be used to distinguish an origin from stem or transit-amplifying
cells. Holoclones and meroclones derived from the prostate cancer
cell line DU145 differ only in the proportion of stem cells each
contains.
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